Savara Inc. (SVRA)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Savara SVRA Sets Annual Meeting Ahead of August FDA Decision
# 🧾 What This Document Is This is a **preliminary proxy statement** (PRE 14A) for Savara Inc. Think of it as a company's official "meeting invitation and agenda" sent to its owners (stockholders). It explains what will be voted on at the upcoming annual meeting and provides the information needed t
SEC filings
All filings →Insider trades
All insider trades →Savara Inc. has no reported insider trades in the last 90 days.